Proto-oncogene amplification and human breast tumor phenotype
about
The product of the EMS1 gene, amplified and overexpressed in human carcinomas, is homologous to a v-src substrate and is located in cell-substratum contact sitesCyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibitionRole of proto-oncogene activation in carcinogenesis.Reduced expression of TGF beta is associated with advanced disease in transitional cell carcinoma.First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer.Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosisLoss of heterozygosity at chromosome 11 in breast cancer: association of prognostic factors with genetic alterations.Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status.DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours.Classical gene amplifications in human breast cancer are not associated with distant solid metastasesEstrogen-dependent cyclin E-cdk2 activation through p21 redistribution.C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevancec-myc reverses neu-induced transformed morphology by transcriptional repression.Prognostic value of c-erbB-2 expression in uterine cervical carcinoma.c-erbB-2 expression in different histological types of invasive breast carcinoma.Chromosomal sites for hepatitis B virus integration in human hepatocellular carcinoma.Cyclin D1 and human neoplasiaBiological indices in the assessment of breast cancer.c-erbB-2 oncogene as a prognostic marker in breast cancer.Oestrogen and epidermal growth factor down-regulate erbB-2 oncogene protein expression in breast cancer cells by different mechanisms.Determination of c-erbB-2 protein in primary breast cancer tissue extract using an enzyme immunoassay.
P2860
Q24605485-DFCAF0AF-13A1-4F74-B327-05D35C8331BFQ24644847-C3F6A21C-C801-4B93-AE75-E7CE46F8893DQ29030215-085098F7-BAE8-45AD-A214-AF3BB47ECC9FQ34844276-F218DA49-77A0-4404-8C5B-36C92547A928Q35976124-12F906E8-B39B-4E77-8711-E81DDE61BD7DQ35976710-2D7F2DBE-6520-49E0-9286-B2E7217619E9Q35982544-7AA087B4-70EF-46AB-B212-9FA901EA6C7FQ36081181-C3C5B5ED-2F8C-4D02-9B69-8AD7EE02EB0EQ36136157-2976F297-CB9F-4EC0-8F54-EA36F23D848BQ36136448-0B29F96D-44AE-4336-A10A-ACCDD67AA073Q36431072-D48D7D32-BE79-4E8E-BA8B-6B1F0904BA36Q36569390-C78D0B4C-709C-4BED-A69B-B9D18E196AE6Q36621638-FE2F1CAE-EC02-4E87-8B4E-27255362312CQ36680741-662B44DB-DFD0-4245-9195-AE3A5F33DA20Q37111228-55E911AD-5221-4BF0-8E37-CFD8746C3D33Q37143922-C25DC16E-AF9C-46BE-90A3-DAA7E9FACE79Q40115711-2F24146D-B902-47F8-BB66-06A0792A1C87Q40794379-C0C521F0-F8A4-4621-9F02-DE7A50875B38Q40848953-82705801-B4E6-4CAB-A75D-626C545B41DCQ42383432-51A8CC4C-0B7B-49FB-863F-F0181E61305DQ42590519-180FE5C8-14F6-46EB-ADC0-75BE8CC64AB3Q55075802-23F11EF3-041C-4FC8-B5B7-BE3C76D2FB35
P2860
Proto-oncogene amplification and human breast tumor phenotype
description
im November 1989 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 November 1989
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 1989
@uk
name
Proto-oncogene amplification and human breast tumor phenotype
@en
Proto-oncogene amplification and human breast tumor phenotype
@nl
type
label
Proto-oncogene amplification and human breast tumor phenotype
@en
Proto-oncogene amplification and human breast tumor phenotype
@nl
prefLabel
Proto-oncogene amplification and human breast tumor phenotype
@en
Proto-oncogene amplification and human breast tumor phenotype
@nl
P2093
P1433
P1476
Proto-oncogene amplification and human breast tumor phenotype
@en
P2093
Jeanteur P
Simony-Lafontaine J
P304
P407
P577
1989-11-01T00:00:00Z